- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
New fillers expanding patients' options
With a handful of new options expected to receive FDA approval withina year, the field of tissue augmentation stands poised to undergo a seismicshift. "The bottom line is, tissue augmentation is about to changedramatically," said Mariano E. Busso, M.D. He is clinical professorin the University of Miami's department of dermatology, chief of dermatologyat Mercy Hospital, also in Miami, Fla., and a private practitioner who isboard-certified in dermatology.
Related Videos
Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis
The Impact of JAK Selectivity in Atopic Dermatitis Treatment
Recapping the Evolving Treatment Landscape for Atopic Dermatitis
Sunscreen Ingredients for UV and Visible Light Protection
The Solar Spectrum and Impact on Skin Health
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis
Related Content
